Remarkably, the tumor inhibition rate of the SFV/IFNg+Pam3 treatment group was higher than that of the SFV/IFNg alone group (59.6% and 49.1%, respectively, versus the corresponding PBS groups). This evidence concerns the gene IFNG and neoplasm.